## **Core Concept**
The question tests knowledge of antitubercular therapy (ATT) drugs and their metabolism, specifically in the context of hepatic dysfunction. Hepatic dysfunction requires consideration of drug metabolism and potential hepatotoxicity.

## **Why the Correct Answer is Right**
The correct answer, , is likely because is primarily excreted by the kidneys and has less hepatotoxicity compared to other ATT drugs. Rifampicin and isoniazid are known for their hepatotoxic potential, whereas is less hepatotoxic and can be safer in patients with hepatic dysfunction.

## **Why Each Wrong Option is Incorrect**
* **Option A:** - This drug is associated with significant hepatotoxicity, making it less suitable for patients with hepatic dysfunction.
* **Option B:** - Similar to option A, this drug also carries a risk of hepatotoxicity.
* **Option D:** - This option is incorrect because, like options A and B, it may not be the best choice for patients with hepatic dysfunction due to potential hepatotoxicity or other pharmacokinetic issues.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that when managing tuberculosis in patients with hepatic dysfunction, it's crucial to choose ATT drugs with lower hepatotoxic potential.

## **Correct Answer:** .